Frontiers in Immunology (Nov 2022)
ImmUniverse Consortium: Multi-omics integrative approach in personalized medicine for immune-mediated inflammatory diseases
- Stefania Vetrano,
- Stefania Vetrano,
- Gerben Bouma,
- Robert J. Benschop,
- Thomas Birngruber,
- Antonio Costanzo,
- Antonio Costanzo,
- G. R. A. M. D’Haens,
- Loredana Frasca,
- Rainer Hillenbrand,
- Lars Iversen,
- Claus Johansen,
- Arthur Kaser,
- Hans J. P. M. Koenen,
- Christa Noehammer,
- Laurent Peyrin-Biroulet,
- Jeroen Raes,
- Leonardo Ricotti,
- Leonardo Ricotti,
- Philip Rosenstiel,
- Venkata P. Satagopam,
- Stefan Schreiber,
- Severine Vermeire,
- Andreas Wollenberg,
- Andreas Wollenberg,
- Stephan Weidinger,
- Daniel Ziemek,
- Silvio Danese,
- Silvio Danese,
- Silvio Danese,
- ImmUniverse Consortium,
- Alessandro Armuzzi,
- Alessia Butera,
- Andrea Cafarelli,
- Lucia Ciglar,
- Ellen van den Bogaard,
- Elke MGJ de Jong,
- Ernst Dow,
- Marjolijn Duijvenstein,
- Ahmed Essaghir,
- Rebecca Favaro,
- Gionata Fiorino,
- Soumyabrata Ghosh,
- Wei Gu,
- Robert Häsler,
- Xuehui He,
- Roberto Lande,
- Judith Logmans,
- Christoph Magnes,
- Karl Nocka,
- Loulou Peisl,
- Samuel Pineda Chavez,
- Angela Sorriento,
- Klemens Vierlinger,
- Laurien Waaijer,
- Xinhui Wang,
- Nicolas Wisniacki,
- Mary Zuniga
Affiliations
- Stefania Vetrano
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
- Stefania Vetrano
- IBD Unit, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano, Italy
- Gerben Bouma
- Clinical Pharmacology and Experimental Medicine, GlaxoSmithKline R&D, United Kingdom
- Robert J. Benschop
- Immunology and Translation, Eli Lilly and Company, Indianapolis, IN, United States
- Thomas Birngruber
- Joanneum Research GmbH, HEALTH - Institute for Biomedicine and Health Sciences, Graz, Austria
- Antonio Costanzo
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
- Antonio Costanzo
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
- G. R. A. M. D’Haens
- Department of Gastroenterology and Hepatology, Academisch Medisch Centrum Bij De Universiteit Van Amsterdam, Amsterdam, Netherlands
- Loredana Frasca
- Pharmacological Research and Experimental Therapy Unit, Istituto Superiore Di Sanità, Roma, Italy
- Rainer Hillenbrand
- Novartis Pharma AG, Basel, Switzerland
- Lars Iversen
- 0Department of Dermatology, Aarhus Universitetshospital, Aarhus, Denmark
- Claus Johansen
- 1Aarhus Universitet, Aarhus C, Denmark
- Arthur Kaser
- 2Division of Gastroenterology and Hepatology, Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, United Kingdom
- Hans J. P. M. Koenen
- 3Department of Laboratory Medicine, Laboratory of Medical Immunology, Stichting Radboud Universitair Medisch Centrum, Nijmegen, Netherlands
- Christa Noehammer
- 4Department of Health and Environment, AIT Austrian Institute of Technology GmbH, Vienna, Austria
- Laurent Peyrin-Biroulet
- 5Department of Gastroenterology, Centre Hospitalier Regional Universitaire Nancy, Nancy, France
- Jeroen Raes
- 6Department of Microbiology and Immunology, Vib Vzw, Gent, Belgium
- Leonardo Ricotti
- 7The BioRobotics Institute, Scuola Superiore Sant’Anna, Pisa, Italy
- Leonardo Ricotti
- 8Department of Excellence in Robotics & AI, Scuola Superiore Sant’Anna, Pisa, Italy
- Philip Rosenstiel
- 9Institute of Clinical Molecular Biology, Christian Albrechts University and University Hospital, Kiel, Germany
- Venkata P. Satagopam
- 0Luxembourg Centre for Systems Biomedicine, House of Biomedicine II, University of Luxembourg, Belvaux, Luxembourg
- Stefan Schreiber
- 1Department of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany
- Severine Vermeire
- 2Department of Gastroenterology and Hepatology, Katholieke Universiteit Leuven, Leuven, Belgium
- Andreas Wollenberg
- 3Department of Dermatology, Ludwig-Maximilian-University Munich, Munich, Germany
- Andreas Wollenberg
- 4Department of Dermatology, Free University Brussels, University Hospital Brussels, Brussels, Belgium
- Stephan Weidinger
- 5Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany
- Daniel Ziemek
- 6Worldwide Research and Development, Pfizer Pharma, Berlin, Germany
- Silvio Danese
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
- Silvio Danese
- 7Department of Gastroenterology and Endoscopy IRCCS Ospedale San Raffaele, Milan, Italy
- Silvio Danese
- 8University Vita-Salute San Raffaele, Milan, Italy
- ImmUniverse Consortium
- Alessandro Armuzzi
- Alessia Butera
- Andrea Cafarelli
- Lucia Ciglar
- Ellen van den Bogaard
- Elke MGJ de Jong
- Ernst Dow
- Marjolijn Duijvenstein
- Ahmed Essaghir
- Rebecca Favaro
- Gionata Fiorino
- Soumyabrata Ghosh
- Wei Gu
- Robert Häsler
- Xuehui He
- Roberto Lande
- Judith Logmans
- Christoph Magnes
- Karl Nocka
- Loulou Peisl
- Samuel Pineda Chavez
- Angela Sorriento
- Klemens Vierlinger
- Laurien Waaijer
- Xinhui Wang
- Nicolas Wisniacki
- Mary Zuniga
- DOI
- https://doi.org/10.3389/fimmu.2022.1002629
- Journal volume & issue
-
Vol. 13
Abstract
Immune mediated inflammatory diseases (IMIDs) are a heterogeneous group of debilitating, multifactorial and unrelated conditions featured by a dysregulated immune response leading to destructive chronic inflammation. The immune dysregulation can affect various organ systems: gut (e.g., inflammatory bowel disease), joints (e.g., rheumatoid arthritis), skin (e.g., psoriasis, atopic dermatitis), resulting in significant morbidity, reduced quality of life, increased risk for comorbidities, and premature death. As there are no reliable disease progression and therapy response biomarkers currently available, it is very hard to predict how the disease will develop and which treatments will be effective in a given patient. In addition, a considerable proportion of patients do not respond sufficiently to the treatment. ImmUniverse is a large collaborative consortium of 27 partners funded by the Innovative Medicine Initiative (IMI), which is sponsored by the European Union (Horizon 2020) and in-kind contributions of participating pharmaceutical companies within the European Federation of Pharmaceutical Industries and Associations (EFPIA). ImmUniverse aims to advance our understanding of the molecular mechanisms underlying two immune-mediated diseases, ulcerative colitis (UC) and atopic dermatitis (AD), by pursuing an integrative multi-omics approach. As a consequence of the heterogeneity among IMIDs patients, a comprehensive, evidence-based identification of novel biomarkers is necessary to enable appropriate patient stratification that would account for the inter-individual differences in disease severity, drug efficacy, side effects or prognosis. This would guide clinicians in the management of patients and represent a major step towards personalized medicine. ImmUniverse will combine the existing and novel advanced technologies, including multi-omics, to characterize both the tissue microenvironment and blood. This comprehensive, systems biology-oriented approach will allow for identification and validation of tissue and circulating biomarker signatures as well as mechanistic principles, which will provide information about disease severity and future disease progression. This truly makes the ImmUniverse Consortium an unparalleled approach.
Keywords
